The newly incorporated company ‘Numaferm’ enables plannable biotechnological production of peptides at higher yields and at lower costs. Evonik invests in this biotechnology company as it identifies it as a growth opportunity for its health care and specialty additives segment.
Essen/Germany – Through its venture capital unit, Evonik has invested in the start-up ‘Numaferm’ and now holds a minority share in the biotechnology company, which is located in Düsseldorf. The investment was made as part of a seed financing round and also includes investments by high-tech Gründerfonds, the Business Angels and Qiagen co-founders Detlev Riesner and Jürgen Schumacher, as well as the European Investment Fund.
Numaferm has developed a technology platform, which enables plannable biotechnological production of peptides at higher yields and at lower costs. The technology can be used for almost all peptides, and production on an industrial scale becomes possible. As a result, new technical applications for peptides also become realistic for the first time.
Peptides and their applications are highly interesting for Evonik’s growth in the health care and specialty additives segment. Numaferm intends to use the fresh capital to drive forward technological development and get the first products to market maturity.
The new company was founded at the beginning of 2017 as a spin-off of the Institute of Biochemistry. Previously, the project was supported by an Exist research transfer of the German Federal Ministry for Economic Affairs and Energy, among others.